In the McCarty lab, we focus on the molecular physiology of ion channels and receptors, with emphasis on epithelial chloride channels. Our specific focus is the pathophysiology of Cystic Fibrosis, including the structure/function of CFTR and its many roles in the airway. We pioneered the use of peptide toxins as probes of chloride channels. We also have projects that study the functional consequences of heterodimerization among GPCRs, the role of CFTR in regulation of sweat composition, and the molecular ecology of predator-prey interactions in the marine environment. Our translational research in CF targets: (a) the mechanism by which the expression of mutant CFTR in airway epithelial cells impacts the development of CF-related diabetes; and (b) identification of biomarkers of acute pulmonary exacerbations in CF along with development of a novel device for their detection in the home. 

The goal of the Center for Cystic Fibrosis Research is to engage Atlanta researchers in basic and translational research that will lead to a better understanding of the pathophysiology of this disease and/or generate new devices and treatments to increase the length and quality of life for CF patients. The novel theme for these research activities is 'The Systems Biology of the CF Lung'.

Chunhui Xu, PhD, is a Professor in the Department of Pediatrics at Emory University School of Medicine and a member of the Cell and Molecular Biology Research Program at Winship Cancer Institute. 

Research in Dr. Xu's laboratory is focused on human cardiomyocytes derived from human pluripotent stem cells, which hold promise for cardiac cell therapy, disease modeling, drug discovery, and the study of developmental biology. They are also collaborating with investigators at Georgia Tech, Emory University, and Children's Healthcare of Atlanta, to explore the application of nanotechnology and tissue engineering in stem cell research.

The goal of Christopher Porter's lab is to develop novel therapeutic strategies for leukemia through better understanding of molecular mechanisms of leukemogenesis and treatment resistance. We employ a wide variety of techniques, in vitro and in vivo, for discovery and validation of molecular vulnerabilities in cancer cells. For example, using a genome-scale shRNA screen, we identified WEE1 as a chemosensitizing target in acute myeloid leukemia (AML) cells. Subsequent studies funded by the NCI have validated this finding and supported the development of a clinical trials a WEE1 inhibitor in subjects with AML. More recently, we have discovered a novel function for the transcription factor ETV6 in regulating normal hematopoiesis and are testing whether and how Etv6 mutation promotes leukemogenesis using a new mouse model with a point mutation in Etv6. Another project in the lab is directed at understanding mechanisms of immune evasion during leukemogenesis, as well as enhancing immune cells’ response to leukemia cells.